, 4 Interestingly, elevated BP (hypertension) has been implicated as a main co-morbidity and a potential risk factor for more severe clinical outcomes of COVID-19,5 , 6 and speculation mounted that this may be due to commonly prescribed antihypertensive medications targeting RAS [i.e. angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II type 1 receptor (AT1) antagonists (ARB)]. This evidence concerns the gene ACE and COVID-19.